Nucleotide metabolism

Roles of nuclotides


- energy storage (central role of ATP)
- nucleotide units for RNA, DNA synthesis
- components of cofactors (NAD, FAD)
- intracellular second messengers (cAMP, cGMP)
- synthesis of activated intermediates (UDP glucose, CDP - choline,
- CDP diacylglycerol, GDP mannose)
- allosteric effectors

General characteristics of nucleotides


- Lactam-lactim tautomerism
- In physiological condition the lactam form is oftener
- Low water solubility is characterictic for purine nucleotides (xanthine, guanine, uric-acid) → on acidic pH it is even worse (!!! gout)
- Sythesis and degradation is different in tissues \rightarrow possible therapic solutions (tumor therapy)
- Structure: nucleobase + five-carbon sugar + phosphate

Genesis of mononucleotides


- de novo sythesis: from amino acids, C1-parts, CO₂, ribose, phosphate
- From nucleotides absorbed and degradated in the gastrointestinalis system – they don't discover the nucleotide needs
- From degradation in tissues by nucleosidase




- Purine nucleotides: adenine, guanine
- Synthesis: ribose \rightarrow IMP (PRPP-sythase) \rightarrow ATP and GTP formation
- Regulation of synthesis (when there are enough end product, synthesis is unnecessary): AMP, GMP, IMP – feedback effect, regulation of PRPP-sythase and PRPP-amidotransferase enzymes, AMP and GMP synthesis regulation




ATP and GTP formation from IMP




Degradation of purin bases



Salvage mechanisms





Uric acid

- solubility is decreased
- when uric acid level increases, it deposes in organism
- keto-enol tautomerism
- advantage: antioxidant
- (in other mammal it is degraded by urokinase, allantion is formed, which has a good water solubility)

Hyperuricaemia (abnormally high level of uric acid in the blood), gout Primary:

- 1. Idiopathic
- 2. Enzyme defects: -HGPRTdeficiency

-ribose-P-diphosphokinase \uparrow

-adenophosphoribosil-transferase \downarrow

3. Decreased renal excretion of uric acid

Secundary:

Increased purin katabolism and turnover

1.Myeloproliferative disorders

- 2.Lymphoproliferative disorders
- 3. Carcinoma and sarcoma
- 4. Chronic hemolitic anemia
- 5. Citotoxic drugs
- 6. Psoriasis


Decreased renal excretion of uric acid

- 1. Intrinsic renal disease
- 2. Functional disorders of tubular transport:

drugs, increased lactate level, hyperketoacidaemia, diabetes insipidus, Bartter-sydrome \rightarrow Urate crystals deposite in joints (tophus formation – gout), in kidneys (kidney stone).


Sympthoms are getting worse on purine-rich diet, in excessive cell damage.

Therapy: allopurinol \rightarrow inhibits the xanthineoxidase \rightarrow inhibits the last step of uric acid synthesis and the de novo purine synthesis.




- Pyrimidine nucleotides: cytosine, thymine, uracil.
- Synthesis: Asp, Gln, CO2 + activated ribose-phosphate

 → dihydro-orotate → in mitochondrion orotate → UMP
 → UDP → UTP → CTP
 ▲ TTP
- Regulation of synthesis: UMP, UTP, CTP feedback mechanisms, enzyme regulations




Formation of pyrimidine nucleoside di- and tripfosphates



Degradation of pyrimidine nucleotides

- During degradation CO2, NH3, β -alanine \rightarrow coA is formed
- UMP, CMP \rightarrow uridine, citidine \rightarrow uracile \rightarrow dihydrouracile \rightarrow N-carbamil- β -alanin dihydropyrimidinase) \rightarrow CO2, NH3, β -alanine \rightarrow coA
- dihydropyrimidinase defect: thymidine level increases in blood, appeares in urine, causes epileptic seizures. Gout doesn't appears, pyrimidine intermediers are water soluble.
- salvage mechanisms

Degradation of pyrimidine bases



Deoxynucleotides

- They are formed by ribonucleotide-reductase komplex
- It is active in fissiparous cells
- The OH-group of the 2. C-atom of ribose will be reducated, H2O will be formed
- Just nukleoside-diphosphate is substrate for this enzyme
- It is a multicomponent enzymesysthem: ribonucleotide reductase (SH protein), tioredoxine (cofactor)
- SH-groups become oxydated (S-S)
- In eucaryotes glutathion-reductase, in procaryotes thyoredoxin-reductase rereducates the cofactor

Influential drugs of nucleotide biosynthesis

- Aim: to inhibit baneful cell proliferationsokat (e.g.: in tumors, in viral infections, in autoimmun diseases)
- They have also side effects on hemopoetic cells, on immunsystem cells, on gamete and enterocytes
- Folate-, purine- és pyrimidine antagonists or analogues.

AMINOPTERIN, METHOTREXATE:

-tetrahidrofolate analogues

-due to the competitive inhibition of dihydrofolate-reductase no N5,N10-metyl-THF is formed

-dUMP will not be metylated to dTMP

SULFONAMIDES:

-analogues of p-amino-benzoeacid (PABA) in folate

-it reduces/inhibits the folate sythesis of bacteria, the nucleotide sythesis of them is also hampered

-it was the first antibacterial drug

6-MERCAPTOPURINE:

-analogue of the hipoxanthine structure

-it is phosphoribosilated by the HGPRT, and so instead of insin acid tioinosin acid is formed, which doesn't transforms to adenilate and guanilate

CITOSINE-ARABINOSIDE:

-it is an antimetabolite, interferes with citosine

-instead of ribose arabinoside is the sugar component

-after phosphorillation it becomes analogue of dCTP, so it inhibits DNS synthesis

5-FLUOROURACILE:

-by kinases it is formed to F-dUMP

-F-dUMP binds kovalent to timidilate sythnase (suicide enzyme)

NUKLEOSIDE ANALOGUES:

-they are the best antiviral drugs (Zovirax®)

-the viral thymidine-kinase is the substrate

-the products inhibit the DNA-polymerates